ArticleBiomolecules2026
Split Intein-Mediated Engineering of Bacteriocins Through Backbone Circularization, Modular Assembly of Chimeras, and Inducible Circularization.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The increasing prevalence of antimicrobial resistance has renewed interest in bacteriocins and other antimicrobial peptides as promising alternatives to conventional antibiotics. In this context, in vitro cell-free protein synthesis (IV-CFPS) provides a rapid and versatile platform for the production and functional evaluation of bacteriocins, enabling antimicrobial screening without the limitations associated with cellular expression, low production yields, or peptide toxicity. In previous studies, we demonstrated the utility of IV-CFPS for the production and characterization of a broad range of bacteriocins. More recently, integration of IV-CFPS with split intein-mediated ligation (SIML) enabled the production and functional evaluation of circular bacteriocins, thereby expanding the repertoire of bacteriocins accessible to cell-free synthesis and screening. Here, we further expand the capabilities of the IV-CFPS/SIML platform through three complementary bacteriocin engineering strategies. First, SIML was applied to the backbone circularization of naturally linear bacteriocins, demonstrating that SIML-mediated circularization can be extended beyond naturally circular bacteriocins. Second, the platform enabled the modular assembly of chimeric bacteriocins through the ligation of the translocation/receptor-binding (T-R) and cytotoxic (C) domains of either the same or different colicins. Finally, we developed a proof-of-concept inducible protein trans-splicing system in which bacteriocin circularization is triggered by the addition of a complementary split intein component, thereby providing temporal control over peptide activation. These results establish IV-CFPS/SIML as a versatile platform for programmable bacteriocin engineering and substantially expand its applications beyond the production of naturally circular bacteriocins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.